EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EyePoint (Nasdaq: EYPT) reported the grant of non-statutory stock options to two new employees as inducement awards under NASDAQ Listing Rule 5635(c)(4), outside its 2023 Long-Term Incentive Plan.

Rhea-AI Summary

EyePoint (Nasdaq: EYPT) reported the grant of non-statutory stock options to two new employees as inducement awards under NASDAQ Listing Rule 5635(c)(4), outside its 2023 Long-Term Incentive Plan. The awards cover options to purchase up to an aggregate of 14,600 shares of common stock.

According to EyePoint, the options were granted on August 14, 2026 at an exercise price of $14.75 per share, equal to the closing market price that day. The options have a 10-year term and vest over four years, with 25% vesting on the first anniversary of the grant date and the remainder vesting monthly over the subsequent three years, subject to continued employment.

Argus Aug 17 session 43 alerts

-66.98% close to close 1136.6x rel. volume Open Argus

Details

News Market Reaction – EYPT

-39.7% Trough in 1 min

$483.19M Market Cap

On Aug 17, the first trading day after this news, EYPT closed 66.98% below the previous close. Argus tracked a trough of -39.7% from its starting point during tracking. Our momentum scanner recorded 43 alerts for this stock that day. Relative volume reached 1136.6x the daily average during tracking.

Data tracked by StockTitan Argus for the Aug 17 session.

Key Figures

Shares underlying options: 14,600 shares Exercise price: $14.75 per share Grant date: August 14, 2026 +4 more

Shares underlying options

14,600 shares

Granted to two new employees

Exercise price

$14.75 per share

Closing price on August 14, 2026

Grant date

August 14, 2026

Stock option awards

Option term

Ten years

Term of the stock options

Vesting period

Four years

Overall vesting schedule

First-year vesting

25%

Vests on the first anniversary of the grant date

Remaining vesting

Three years

Equal monthly installments after the first anniversary

Historical Context

5 past events · Latest: Aug 05

5 events

1. Aug 05

   earnings report

   24h Move

   +5.0%

   Quarterly revenue declined while operating expenses and net loss increased.

2. Jul 30

   clinical trial enrollment

   24h Move

   +7.9%

   Both pivotal Phase 3 DME trials completed enrollment ahead of schedule.

3. Jul 16

   inducement stock grants

   24h Move

   -5.8%

   Options covering 63,500 shares were granted to two new employees.

4. Jul 13

   leadership appointment

   24h Move

   -3.0%

   Tarek S. Hassan joined as Chief Strategic Science Officer.

5. Jun 16

   inducement stock grants

   24h Move

   +6.6%

   Options covering 39,700 shares were granted to three new employees.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

non-statutory stock options, inducement awards, nasdaq listing rule 5635(c)(4)

3 terms

non-statutory stock options financial

"The Company granted non-statutory stock options to new employees"

Non-statutory stock options are a type of reward that companies give to employees, allowing them to buy company shares at a set price within a certain period. Unlike formal or government-approved plans, these options are more flexible but may have different tax implications. For investors, they can influence a company's stock price and financial health, making them an important factor to consider.

inducement awards financial

"outside the Company’s 2023 Long-Term Incentive Plan in accordance with"

Inducement awards are special bonuses given to new employees to encourage them to join a company, often in the form of stock or money. They matter because they can motivate talented people to choose one company over another and help align their success with the company's growth. Think of it like a signing bonus to seal the deal.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with NASDAQ Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WATERTOWN, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).

The Company granted stock options to purchase up to an aggregate of 14,600 shares of EyePoint common stock to two new employees. The stock options were granted on August 14, 2026. The grants were approved by the Compensation Committee and made as an inducement material to each employee entering into employment with EyePoint in accordance with NASDAQ Listing Rule 5635(c)(4). The option awards have an exercise price of $14.75 per share, the closing price of EyePoint’s common stock on August 14, 2026. The options have a ten-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee’s date of grant and the remainder vesting in equal monthly installments over the following three years. Vesting of the options is subject to the employee’s continued service with EyePoint through the applicable vesting dates.

About EyePoint

EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU™, is an innovative investigational sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, in next-generation bioerodible Durasert E™ technology. Supported by robust safety and efficacy data across multiple clinical trials and indications, DURAVYU is currently being evaluated in Phase 3 pivotal trials for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Topline data is expected for wet AMD beginning in August 2026 and for DME in the fourth quarter of 2027.

The Company is committed to partnering with the retinal community to improve patient lives while creating long-term value, with four approved drugs over three decades and tens of thousands of eyes treated with EyePoint innovation.

EyePoint is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts.

Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.

DURAVYU^™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.

Investors:
Robin Garner
EyePoint, Inc.
ir@eyepoint.bio

Media:
Helen O’Gorman
FTI Consulting
media@eyepoint.bio

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What inducement stock option grants did EyePoint (EYPT) announce on August 14, 2026?

EyePoint announced non-statutory stock option grants for two new employees covering up to 14,600 shares of common stock. According to EyePoint, these inducement awards were granted outside the 2023 Long-Term Incentive Plan under NASDAQ Listing Rule 5635(c)(4) as a condition of employment.

What are the key terms of the EyePoint (EYPT) inducement options granted in August 2026?

The inducement options have a 10-year term and an exercise price of $14.75 per share. According to EyePoint, the price equals the August 14, 2026 closing share price, and vesting depends on each employee’s continued service with the company through applicable vesting dates.

How do the EyePoint (EYPT) inducement options vest for the new employees?

The options vest over four years, with 25% vesting on the first anniversary of the grant date. According to EyePoint, the remaining 75% vests in equal monthly installments over the next three years, contingent on continued employment with the company.

Why were the EyePoint (EYPT) inducement grants made outside the 2023 Long-Term Incentive Plan?

The stock options were granted as inducement awards to attract new employees, outside the 2023 Long-Term Incentive Plan. According to EyePoint, this structure complies with NASDAQ Listing Rule 5635(c)(4), which permits equity grants as a material inducement to employment.

What does NASDAQ Listing Rule 5635(c)(4) mean for EyePoint (EYPT) shareholders?

NASDAQ Listing Rule 5635(c)(4) allows EyePoint to issue equity awards as employment inducements without prior shareholder approval. According to EyePoint, the August 14, 2026 options for 14,600 shares were made under this rule and may modestly increase the potential share count if exercised.